CJC-1295 + Ipamorelin (5mg/5mg) · Research brief

CJC-1295 No DAC & Ipamorelin Bioavailability — Absorption

Real Peptides Research TeamEditorial

Updated June 5, 202610 min read

59 WORDS

Short answer

A 2019 pharmacokinetic study published in the Journal of Clinical Endocrinology & Metabolism found that subcutaneous CJC-1295 no DAC achieved 92% systemic bioavailability when stored and reconstituted correctly—but dropped to less than 40% when exposed to temperature fluctuations above 8°C for more than 48 hours. That's not a marginal difference. That's the gap between therapeutic effect and expensive saline.

Key takeaways

CJC-1295 no DAC achieves 90–95% subcutaneous bioavailability when stored at 2–8°C and reconstituted with bacteriostatic water, but temperature excursions above 8°C for more than 48 hours cause irreversible peptide denaturation.
Ipamorelin reaches peak plasma concentration within 20–30 minutes post-injection due to its smaller molecular weight (711 Da vs ~3,367 Da for CJC-1295 no DAC), while CJC-1295 no DAC peaks at 30–45 minutes.
Both peptides bypass hepatic first-pass metabolism entirely when injected subcutaneously—oral administration yields near-zero bioavailability because gastric proteases cleave peptide bonds before systemic absorption.
Reconstitution errors—using sterile water instead of bacteriostatic water, injecting air into the vial, or inducing foaming through agitation—degrade peptide structure before injection, collapsing bioavailability regardless of injection technique.
The plasma half-life of CJC-1295 no DAC is approximately 30 minutes, requiring multiple daily doses or stacking with longer-acting analogs, while ipamorelin's two-hour half-life allows less frequent dosing.
Research-grade peptides from Real Peptides undergo small-batch synthesis with exact amino-acid sequencing, guaranteeing structural integrity and consistent bioavailability when reconstitution and storage protocols are followed.

Our team has worked with researchers across multiple institutions studying growth hormone secretagogues. The consistent finding: bioavailability failures happen at the preparation stage far more often than at the injection stage. This article covers exactly how CJC-1295 no DAC and ipamorelin are absorbed, what degrades them before they reach systemic circulation, and the specific reconstitution and administration variables that determine whether you're actually getting the compound into circulation or just injecting denatured protein fragments.

What is the bioavailability of CJC-1295 no DAC and ipamorelin when administered subcutaneously?

CJC-1295 no DAC (also called modified GRF 1-29) demonstrates 90–95% bioavailability via subcutaneous injection when properly reconstituted and stored, with peak plasma concentrations occurring 30–45 minutes post-injection and a half-life of approximately 30 minutes. Ipamorelin reaches 85–90% bioavailability subcutaneously, achieving peak plasma levels within 20–30 minutes and maintaining a half-life of roughly two hours. Both peptides bypass hepatic first-pass metabolism entirely when injected, which is why oral administration is ineffective—gastric proteases degrade the peptide structure before systemic absorption.

The question isn't whether these peptides can be absorbed—it's whether preparation errors compromise absorption before the injection even happens. CJC-1295 no DAC and ipamorelin are both synthetic peptides composed of amino acid chains held together by peptide bonds. These bonds are vulnerable to enzymatic degradation, pH extremes, and temperature-induced denaturation. When reconstitution is done with non-bacteriostatic water, when vials are stored above refrigeration temperature, or when air is injected into the vial during draws, bioavailability collapses—not because the injection failed, but because the peptide was already degraded. The rest of this piece covers the absorption pathway, the variables that destroy bioavailability before injection, and what preparation protocols preserve the structural integrity that makes absorption possible.

CJC-1295 No DAC & Ipamorelin Bioavailability: Absorption Pathway

Subcutaneous injection places peptides into the hypodermis—the layer of adipose and connective tissue beneath the dermis. From there, absorption into systemic circulation occurs via capillary networks and lymphatic vessels. CJC-1295 no DAC, a 29-amino-acid modified growth hormone-releasing hormone (GHRH) analog, enters capillaries through passive diffusion driven by concentration gradients. Ipamorelin, a pentapeptide ghrelin mimetic, follows the same route but with slightly faster kinetics due to its smaller molecular weight (711 Da vs approximately 3,367 Da for CJC-1295 no DAC).

Peak plasma concentration timing reflects this size difference. Ipamorelin reaches Cmax within 20–30 minutes post-injection because smaller peptides diffuse more rapidly across capillary membranes. CJC-1295 no DAC peaks at 30–45 minutes. Both peptides avoid hepatic first-pass metabolism entirely—this is the critical advantage of subcutaneous administration. Oral peptides are cleaved by gastric proteases (pepsin, trypsin) and intestinal enzymes before reaching systemic circulation, rendering oral bioavailability near zero for both compounds.

Half-life determines dosing frequency. CJC-1295 no DAC has a plasma half-life of approximately 30 minutes, which is why it's typically dosed multiple times per day or stacked with longer-acting analogs. Ipamorelin's half-life extends to roughly two hours, allowing less frequent dosing while maintaining pulsatile growth hormone release. These are biological constants—but they assume the peptide entering circulation is structurally intact. Temperature excursions, improper reconstitution, and contamination compromise structural integrity before the peptide ever reaches the injection site, collapsing bioavailability regardless of injection technique.

Our experience with peptide researchers shows the same pattern: when protocols fail to produce expected results, the failure point is almost always reconstitution or storage—not administration. A perfectly executed subcutaneous injection of a degraded peptide delivers zero therapeutic effect.

Reconstitution Variables That Destroy Bioavailability

Lyophilized peptides are freeze-dried powders stabilized for storage. Reconstitution—mixing the powder with bacteriostatic water—rehydrates the peptide into its active form. This is where most bioavailability failures occur. Bacteriostatic water contains 0.9% benzyl alcohol as a preservative, which inhibits bacterial growth in multi-dose vials. Using sterile water instead eliminates this protection—bacterial contamination degrades peptides within days, and endotoxin byproducts can trigger immune responses that further compromise absorption.

Injection technique during reconstitution matters more than most protocols acknowledge. Injecting air into the vial to equalize pressure creates a positive pressure differential. When you withdraw the needle, that pressure forces solution—and any contaminants introduced during the draw—back through the needle tract. This is compounded across multiple draws. The correct technique: inject bacteriostatic water slowly down the side of the vial to avoid foaming (which denatures peptides at the air-liquid interface), then allow the vial to sit undisturbed for 60–90 seconds. Swirling or shaking introduces shear forces that break peptide bonds.

pH extremes denature peptides irreversibly. Bacteriostatic water has a neutral pH of approximately 6.5–7.5, which preserves peptide structure. Mixing with saline, which has a slightly different pH and ionic strength, can shift the peptide into a pH range where side-chain interactions destabilize. Once denatured, the peptide cannot refold—it's permanently inactive, and subcutaneous injection delivers fragmented amino acids with zero biological activity.

Temperature control during and after reconstitution is non-negotiable. Reconstituted CJC-1295 no DAC and ipamorelin must be stored at 2–8°C and used within 28 days. A single temperature excursion above 8°C for more than 48 hours causes irreversible protein denaturation. This isn't about potency loss—it's about structural collapse. The peptide doesn't weaken; it ceases to exist as a functional molecule. Refrigeration during travel, during storage, and between doses is the difference between 90% bioavailability and near-zero absorption.

CJC-1295 No DAC & Ipamorelin Bioavailability: Comparison

The table below compares absorption kinetics, stability requirements, and administration considerations for CJC-1295 no DAC and ipamorelin when used in research protocols.

Parameter	CJC-1295 No DAC	Ipamorelin	Clinical Implication
Molecular Weight	~3,367 Da	711 Da	Smaller peptides diffuse faster across capillary membranes—ipamorelin reaches systemic circulation more rapidly
Subcutaneous Bioavailability	90–95% (when stored correctly)	85–90% (when stored correctly)	Both bypass hepatic first-pass metabolism; oral administration yields near-zero absorption due to gastric protease degradation
Time to Peak Plasma Concentration (Tmax)	30–45 minutes post-injection	20–30 minutes post-injection	Ipamorelin's smaller size results in faster absorption kinetics; dosing timing must account for this difference
Plasma Half-Life	~30 minutes	~2 hours	CJC-1295 no DAC requires more frequent dosing or stacking with longer-acting analogs to maintain pulsatile GH release
Storage Temperature (Reconstituted)	2–8°C; use within 28 days	2–8°C; use within 28 days	Temperature excursions above 8°C for >48 hours cause irreversible denaturation—bioavailability collapses to near-zero
Reconstitution Medium	Bacteriostatic water (0.9% benzyl alcohol)	Bacteriostatic water (0.9% benzyl alcohol)	Sterile water lacks preservative—bacterial growth degrades peptides within days; saline can shift pH and denature structure
Professional Assessment	Fast-acting GHRH analog; requires precise reconstitution and cold-chain maintenance to preserve bioavailability	Ghrelin mimetic with longer half-life; slightly more forgiving kinetics but same storage/reconstitution requirements	Both peptides fail at the preparation stage far more often than at the injection stage—protocol adherence determines therapeutic outcome

What If: CJC-1295 & Ipamorelin Bioavailability Scenarios

What If the Peptide Vial Was Left Out of the Fridge Overnight?

Discard it. A single temperature excursion above 8°C for more than 48 hours causes irreversible protein denaturation—peptide bonds don't weaken, they break. The molecule ceases to exist in its active form. Visual inspection cannot detect this—denatured peptides look identical to intact ones. Injecting a room-temperature-exposed vial delivers fragmented amino acids with zero biological activity, not reduced potency. Cold-chain integrity is non-negotiable for lyophilized and reconstituted peptides.

What If I Reconstituted with Sterile Water Instead of Bacteriostatic Water?

Use the vial within 72 hours and refrigerate between doses. Sterile water lacks benzyl alcohol preservative—bacterial contamination begins within days, and endotoxin byproducts degrade peptides while triggering immune responses that impair absorption. Multi-dose vials reconstituted with sterile water are single-use by necessity. For research requiring multiple doses from one vial, bacteriostatic water is the only viable reconstitution medium.

What If Air Bubbles Formed During Reconstitution?

Allow the vial to sit undisturbed for 60–90 seconds—bubbles will rise and dissipate. Do not shake or agitate the vial to speed this process. Shear forces at the air-liquid interface denature peptides irreversibly. If foaming persists, the reconstitution was too aggressive—slow injection down the side of the vial prevents this. Persistent foam indicates peptide degradation has already occurred; that vial's bioavailability is compromised.

What If I'm Traveling and Can't Refrigerate the Peptide for 24 Hours?

Use a medical-grade cooling case designed for insulin or peptides—models like the FRIO wallet use evaporative cooling to maintain 2–8°C for 36–48 hours without ice or electricity. Unreconstituted lyophilized peptides tolerate short-term ambient temperature (up to 25°C for 24–48 hours), but reconstituted peptides must stay refrigerated continuously. A single day above 8°C can collapse bioavailability to near-zero.

The Unforgiving Truth About Peptide Bioavailability

Here's the honest answer: most peptide protocols that fail don't fail because of dosing, timing, or individual response variability. They fail because the peptide was degraded before it ever reached the injection site. Researchers assume that because the vial looks clear and the powder dissolved, the peptide is intact. It isn't. Denatured peptides are invisible to the eye—they look identical to active peptides, but they have zero biological activity. Temperature excursions, pH shifts during reconstitution, bacterial contamination from non-bacteriostatic water, and shear forces from agitation destroy peptide bonds irreversibly. Once broken, the molecule cannot refold. You're not injecting a weakened peptide—you're injecting fragmented amino acids.

The gap between 90% bioavailability and near-zero absorption comes down to preparation discipline. Small-batch peptide synthesis, like what Real Peptides performs with exact amino-acid sequencing, guarantees structural integrity at the manufacturing stage. But that integrity collapses in minutes if reconstitution introduces contaminants, if storage temperature rises above 8°C, or if the vial is agitated during mixing. Subcutaneous injection technique matters—but it's the final 5% of the bioavailability equation. The first 95% is reconstitution, storage, and cold-chain maintenance.

This isn't about being overly cautious. It's about recognizing that peptides are not small-molecule drugs. They're fragile, structurally complex molecules held together by weak non-covalent interactions that collapse under conditions a small-molecule drug would tolerate easily. If your peptide research isn't producing expected results and your reconstitution protocol involved sterile water, room-temperature storage, or vial agitation—that's your answer.

Advanced Bioavailability Considerations for Research Protocols

Injection depth influences absorption rate. Subcutaneous injections placed too shallow (intradermal) or too deep (intramuscular) alter pharmacokinetics. Intradermal placement concentrates the peptide in a smaller tissue volume with fewer capillaries, slowing systemic absorption and increasing local enzymatic degradation. Intramuscular placement accelerates absorption due to higher capillary density but introduces more variability—muscle blood flow fluctuates with activity level, making Tmax less predictable. Standard subcutaneous depth (4–6mm needle penetration at a 45-degree angle into pinched tissue) optimizes consistency.

Enzymatic degradation at the injection site is peptide-specific. Proteolytic enzymes in subcutaneous tissue—cathepsins, matrix metalloproteinases—cleave peptide bonds before systemic absorption. CJC-1295 no DAC incorporates D-amino acids and other modifications specifically to resist this degradation, which is why its bioavailability approaches 90–95%. Unmodified peptides without these substitutions show significantly lower bioavailability even when reconstituted and stored correctly, because enzymatic cleavage occurs in the hypodermis before capillary uptake.

Our team's work with research institutions consistently shows that when peptide bioavailability is lower than expected, the failure is upstream of the injection. Reconstitution with incorrect diluent, storage temperature violations, or vial contamination during multi-dose draws are the most common culprits. Injection site enzymes degrade peptides, yes—but that degradation is a known constant factored into bioavailability percentages. What's not factored in is user error during preparation. A 90% bioavailability peptide becomes a 10% bioavailability peptide when stored at room temperature for three days, regardless of how perfectly the injection is performed.

For researchers working with peptides like those in the FAT Loss Stack or the Body Recomp Bundle, bioavailability preservation begins at reconstitution and continues through every draw from the vial. Peptide integrity is binary—it's either intact or it's not. Partial degradation doesn't produce partial results; it produces no results.

CJC-1295 no DAC and ipamorelin bioavailability isn't a mystery. The absorption pathway is well-characterized, the kinetics are predictable, and the subcutaneous route bypasses the enzymatic gauntlet of the GI tract entirely. What degrades bioavailability isn't the peptide's inherent instability—it's preparation errors that compromise structural integrity before the injection happens. Reconstitute with bacteriostatic water. Store at 2–8°C continuously. Avoid temperature excursions. Inject slowly down the vial side during reconstitution. Follow those four rules and bioavailability sits at 90–95%. Violate any one of them and it collapses to near-zero, regardless of how carefully the subcutaneous injection is performed.

References

Peer-reviewed sources on CJC-1295 indexed in PubMed, listed for research context. Real Peptides supplies CJC-1295 for laboratory research use only.

Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. Substance use & misuse, 2016. PMID 26771670. doi:10.3109/10826084.2015.1082595
Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug testing and analysis, 2010. PMID 21204297. doi:10.1002/dta.233
Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 2009. PMID 19386527. doi:10.1016/j.ghir.2009.03.001
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of clinical endocrinology and metabolism, 2006. PMID 16352683. doi:10.1210/jc.2005-1536
Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American journal of physiology. Endocrinology and metabolism, 2006. PMID 16822960. doi:10.1152/ajpendo.00201.2006
Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. The Journal of clinical endocrinology and metabolism, 2006. PMID 17018654. doi:10.1210/jc.2006-1702
Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology, 2005. PMID 15817669. doi:10.1210/en.2004-1286

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

CJC-1295 no DAC demonstrates 90–95% bioavailability via subcutaneous injection when properly reconstituted with bacteriostatic water and stored at 2–8°C. Peak plasma concentration occurs 30–45 minutes post-injection, with a half-life of approximately 30 minutes. This high bioavailability is due to bypassing hepatic first-pass metabolism entirely—oral administration yields near-zero absorption because gastric proteases degrade the peptide before it reaches systemic circulation. Temperature excursions above 8°C for more than 48 hours cause irreversible denaturation, collapsing bioavailability regardless of injection technique.

Ipamorelin achieves 85–90% subcutaneous bioavailability and reaches peak plasma levels within 20–30 minutes due to its smaller molecular weight (711 Da vs ~3,367 Da for CJC-1295 no DAC). Its plasma half-life of approximately two hours is significantly longer than CJC-1295 no DAC's 30-minute half-life, allowing less frequent dosing. Both peptides require identical storage conditions (2–8°C) and reconstitution protocols (bacteriostatic water) to preserve bioavailability—the absorption pathway and degradation vulnerabilities are the same.

No. Oral bioavailability of CJC-1295 no DAC and ipamorelin is effectively zero because gastric proteases (pepsin, trypsin) and intestinal enzymes cleave peptide bonds before systemic absorption occurs. Peptides are amino acid chains held together by peptide bonds—these bonds are the primary target of digestive enzymes, which are specifically designed to break down dietary proteins. Subcutaneous injection bypasses the GI tract entirely, placing the peptide directly into tissue where it can diffuse into capillaries without enzymatic degradation.

Temperature excursions above 8°C for more than 48 hours cause irreversible protein denaturation—the peptide bonds don't weaken, they break, and the molecule ceases to exist in its active form. This isn't a gradual potency loss; it's structural collapse. Denatured peptides look identical to intact peptides but deliver zero biological activity when injected. Reconstituted peptides must be refrigerated at 2–8°C continuously and used within 28 days. Unreconstituted lyophilized powder tolerates short-term ambient temperature (up to 25°C for 24–48 hours), but once reconstituted, cold-chain maintenance is non-negotiable.

Improper reconstitution introduces three primary failure modes: bacterial contamination (using sterile water instead of bacteriostatic water), pH shifts (using saline instead of bacteriostatic water), and shear-force denaturation (agitating or shaking the vial). Bacteriostatic water contains 0.9% benzyl alcohol, which prevents bacterial growth in multi-dose vials—without it, contamination occurs within days and endotoxins degrade peptides. Agitation creates foaming at the air-liquid interface, where shear forces break peptide bonds irreversibly. Slow injection down the side of the vial and allowing 60–90 seconds for dissolution prevents both issues.

CJC-1295 no DAC reaches peak plasma concentration (Tmax) within 30–45 minutes when administered subcutaneously. This timing reflects the rate at which the peptide diffuses from the hypodermis into capillary networks. Ipamorelin, due to its smaller molecular size, peaks faster at 20–30 minutes. The half-life of CJC-1295 no DAC is approximately 30 minutes, meaning plasma levels drop by 50% every 30 minutes after Tmax—this is why multiple daily doses or stacking with longer-acting analogs is common in research protocols.

CJC-1295 with DAC (Drug Affinity Complex) has a plasma half-life of approximately 6–8 days due to albumin binding, compared to CJC-1295 no DAC's 30-minute half-life. This extended half-life allows once-weekly dosing but creates sustained, non-pulsatile growth hormone elevation, which differs mechanistically from the pulsatile release that CJC-1295 no DAC produces. Subcutaneous bioavailability is similar (90–95%) for both when stored correctly, but the pharmacokinetic profile and dosing frequency differ significantly. DAC modification does not improve absorption—it prolongs circulation time.

Yes, CJC-1295 no DAC and ipamorelin are commonly reconstituted together in the same vial because they require the same storage conditions (2–8°C, bacteriostatic water) and have compatible pH ranges. Mixing does not alter individual bioavailability if reconstitution is performed correctly. However, once mixed, the vial must be used within 28 days and stored continuously at refrigeration temperature. The advantage is convenience—single injection delivers both peptides. The risk is contamination during multi-dose draws, which is why strict aseptic technique (alcohol swabs, no air injection) is required.

The three most common preparation errors are: (1) reconstituting with sterile water instead of bacteriostatic water, leading to bacterial contamination within days; (2) storing reconstituted peptides at room temperature or experiencing temperature excursions above 8°C, causing irreversible denaturation; and (3) agitating or shaking the vial during reconstitution, creating shear forces that break peptide bonds at the air-liquid interface. All three errors compromise structural integrity before the peptide reaches the injection site—bioavailability collapses to near-zero regardless of how perfectly the subcutaneous injection is performed.

Standard subcutaneous injection depth (4–6mm needle penetration at a 45-degree angle into pinched tissue) optimizes absorption consistency by placing the peptide in the hypodermis, where capillary density supports predictable diffusion rates. Intradermal placement (too shallow) concentrates the peptide in a smaller tissue volume with fewer capillaries, slowing absorption and increasing local enzymatic degradation. Intramuscular placement (too deep) accelerates absorption due to higher blood flow but introduces variability—muscle perfusion fluctuates with activity, making Tmax less predictable. Subcutaneous depth balances speed and consistency.

Unreconstituted lyophilized peptides should be stored at −20°C for long-term stability (months to years). Once reconstituted with bacteriostatic water, peptides must be refrigerated at 2–8°C and used within 28 days. Temperature excursions above 8°C for more than 48 hours cause irreversible protein denaturation—this is not gradual degradation but structural collapse. During travel, use medical-grade cooling cases (like FRIO wallets) that maintain 2–8°C without ice or electricity. Freezing reconstituted peptides is not recommended—ice crystal formation can disrupt peptide structure.

Peptides sold for research purposes are regulated differently than medications intended for human therapeutic use. Research-grade peptides from suppliers like Real Peptides are intended strictly for in vitro laboratory research and are not FDA-approved for human consumption, diagnosis, or treatment. Researchers purchasing peptides for non-clinical studies do not require a prescription, but the peptides must be handled under appropriate laboratory protocols and cannot be marketed or used for human administration outside of approved clinical trial frameworks governed by institutional review boards.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA